Knight Therapeutics Inc. provided revenue guidance for the fiscal year 2024. For the period, the company expected to generate revenues between $335 million to $350 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.94 CAD | -2.62% | +0.51% | +14.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.45% | 440M | |
+7.91% | 72.81B | |
+12.64% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-16.90% | 2.48B | |
-26.13% | 2.32B | |
+19.31% | 2.17B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024